Clinical neuropsychiatry
October 1, 2023
Mario Miniati, Graziella Orrù, Mery Paroli et al.
7 citations
Chronic pain patients with higher levels of mindfulness attitudes report less distress, anxiety, and depressive symptoms, and greater physical and general well-being, regardless of whether their pain is oncologic or non-oncologic. In a study of 50 patients, those scoring above a mindfulness threshold (26 of 50) had significantly lower scores on measures of pain-related disability, perceived stress, anxiety, and depression, and higher scores on psychological well-being. Mindfulness level was the strongest positive predictor of well-being, while anxiety and pain intensity were negative predictors.
Expert review of neurotherapeutics
February 1, 2025
Donatella Marazziti, Francesco Weiss, Riccardo Gurrieri et al.
4 citations
After decades of neglect, psychedelics are again being studied for clinical use, but the current enthusiasm risks overstating their benefits and downplaying their harms. The authors review the literature to give a balanced account of both therapeutic potential and risks. Psychedelics show promise for many conditions and appear to have limited risk of abuse or dependence when given under controlled conditions by trained staff. However, many questions remain, and more research is needed to identify which patients and conditions will benefit and which face greater risk of adverse effects.
Expert Opinion on Pharmacotherapy
March 24, 2026
Donatella Marazziti, Matteo Gambini, Riccardo Gurrieri et al.
After decades of limited use, psychedelic compounds are reemerging as potential treatments for mental disorders that do not respond to existing therapies. This narrative review examines the current clinical and regulatory landscape of psychedelic-assisted therapies, covering ketamine, esketamine, MDMA, psilocybin, LSD, DMT, 5-MeO-DMT, and ibogaine for conditions like major depressive disorder, PTSD, and substance use disorders. The authors argue that these therapies will not follow standard prescription models but require specialist-delivered, psychotherapy-integrated care. Late-stage trials show promise for high-need populations, but unresolved challenges around long-term safety, scalability, workforce training, equity of access, and legal accountability remain.